Description
Olmutinib is an inhibitor of EGFR. It is selective for mutant forms of EGFR, leading to cell death of EGFR-expressing tumor cells. Olmutinib reverses ABCG2-mediated multidrug resistance in cancer cells.
Product Unit Size | Cost | Quantity | Stock |
---|
Olmutinib is an inhibitor of EGFR. It is selective for mutant forms of EGFR, leading to cell death of EGFR-expressing tumor cells. Olmutinib reverses ABCG2-mediated multidrug resistance in cancer cells.
Cas No. | 1353550-13-6 |
---|---|
Purity | ≥98% |
Formula | C26H26N6O2S |
Formula Wt. | 486.59 |
Chemical Name | N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide |
IUPAC Name | N-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide |
Synonym | HM61713, BI-1482694 |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Zhang W., Fan Y., et al. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Front Pharmacol. 9:1097 (2018). PMID: 30356705.
Noh Y., Yoon S., et al. A Safety, Pharmacokinetic, Pharmacogenomic and Population Pharmacokinetic Analysis of the Third-Generation EGFR TKI, Olmutinib (HM61713), After Single Oral Administration in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2019. PMID: 31125491.
B-Raf and c-Raf inhibitor.
JAK2 inhibitor.
NS3/4A inhibitor
p110δ PI3K inhibitor.
Androgen receptor downregulator.
Side chain commonly attached to taxanes.
Endogenous proneurotensin peptide, involved in ...
Imidazole; 14-α demethylase inhibitor.
1,8-Diaza-anthracene-tetrone; JNK and ERK5 inhi...
COVID-19 research
Calcium channel blocker.
CHK1 inhibitor.
LBQ657 prodrug; neprilysin inhibitor.
Synthetic progestogen; contraceptive.
Fluorinated aminopropyl carbazole, neuroprotect...
Endogenous peptide; FPRL1/2 agonist.
Dual kinase and GTPase inhibitor.
Expectorant.
ET-A/B antagonist.
p38 MAPK inhibitor.